JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $29
Author: Benzinga Newsdesk | October 01, 2025 07:46am
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and raises the price target from $20 to $29.